Moleculin Biotech Inc. (NASDAQ: MBRX) announced the expansion of its Phase 3 MIRACLE clinical trial for acute myeloid leukemia treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE